News AACR 2025: MaaT Pharma, the gut microbiome, and immuno-oncol... Lyon, France-based late-stage clinical biotech MaaT Pharma has presented new preclinical data for MaaT034 at AACR 2025.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.